Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrizio Mattei

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Nature Immunology|September 17, 2024
Author Correction: Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1BMartina Musella, Andrea Guarracino, Nicoletta Manduca, et al.
Science (New York, N.Y.)|October 31, 2015
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1Erika Vacchelli, Yuting Ma, Elisa E Baracco, et al.
Nature Immunology|August 24, 2022
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1BMartina Musella, Andrea Guarracino, Nicoletta Manduca, et al.
The Journal of Clinical Investigation|July 17, 2025
Aggressive B-cell lymphomas retain ATR-dependent determinants of T-cell exclusion from the Germinal Center Dark ZoneValeria Cancila, Giorgio Bertolazzi, Allison Sy Chan, et al.
Oncotarget|December 25, 2014
Classification of current anticancer immunotherapiesLorenzo Galluzzi, Erika Vacchelli, José-Manuel Bravo-San Pedro, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Nature Immunology|September 17, 2024
Author Correction: Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1BMartina Musella, Andrea Guarracino, Nicoletta Manduca, et al.
Science (New York, N.Y.)|October 31, 2015
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1Erika Vacchelli, Yuting Ma, Elisa E Baracco, et al.
Nature Immunology|August 24, 2022
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1BMartina Musella, Andrea Guarracino, Nicoletta Manduca, et al.
The Journal of Clinical Investigation|July 17, 2025
Aggressive B-cell lymphomas retain ATR-dependent determinants of T-cell exclusion from the Germinal Center Dark ZoneValeria Cancila, Giorgio Bertolazzi, Allison Sy Chan, et al.
Oncotarget|December 25, 2014
Classification of current anticancer immunotherapiesLorenzo Galluzzi, Erika Vacchelli, José-Manuel Bravo-San Pedro, et al.
Pageof 7